ISAI

ISAI is structured around an unusual constraint: its limited partners are themselves French tech entrepreneurs and operators, which means every check is, in some sense, recycled exit proceeds. That setup shapes how the firm behaves at the table. The Paris-based fund has been investing since 2010 across software, marketplaces, and increasingly applied AI, with a recent pull toward health IT as healthcare workflows become more receptive to SaaS.

The healthcare slice of ISAI’s mandate sits inside a broader B2B software thesis. Within health, the focus is health IT and healthcare software, particularly tools that look and sell like enterprise SaaS rather than regulated medical products. The firm tends to favor founders building horizontal software that solves a specific operational pain in clinics, hospitals, or payer environments, where the buyer is closer to a CIO or operations leader than a clinical committee. Portfolio details in healthcare are not enumerated in the source, but the firm’s broader track record in French and European software is the relevant signal.

ISAI invests at Pre-Seed, Seed, and Series A, writing checks of one to five million dollars. The geographic center of gravity is France with selective activity across Europe, and its entrepreneur LP base gives it unusual reach into French operator networks for distribution and hiring. For health tech founders, that network is most useful in the early commercial phase, when introductions to GPs and CIOs at French groups can compress months of cold outreach.

The team is built around partners who have themselves founded or operated technology businesses, with the explicit pitch that founders are talking to people who have done the job. Specific partner names are not provided in the source material, so founders should clarify ownership of the healthcare thesis directly.

The right reason to bring ISAI into a round is the combination of early-stage discipline, French operator access, and a partner base that thinks like founders rather than analysts. The wrong reason is to use the fund as a generalist Series A signal in a deeply regulated subsector; ISAI is more comfortable in software-shaped opportunities than in clinically heavy ones. Founders should expect questions on go-to-market velocity, sales motion design, and product wedge, and should be prepared to talk specifically about how the entrepreneur LP base would be deployed into the company’s first twelve months. The firm rewards crisp, commercial thinking and tends to be skeptical of decks that lean too heavily on regulatory tailwinds without a concrete buyer story attached.